ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials

Neil M. Bressler,Wesley T. Beaulieu,Susan B. Bressler,Adam R. Glassman,B. Michele Melia,Lee M. Jampol,Chirag Jhaveri,Hani Salehi-Had,Gisela Velez,Jennifer K. Sun

ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials

2019

Neil M. Bressler
Wesley T. Beaulieu
Susan B. Bressler
Adam R. Glassman
B. Michele Melia
Lee M. Jampol
Chirag Jhaveri
Hani Salehi-Had
Gisela Velez
Jennifer K. Sun

Purpose:To investigate whether anti–vascular endothelial growth factor (anti-VEGF) for diabetic macular edema or proliferative diabetic retinopathy (PDR) increases the risk of traction retinal detachment (TRD) among eyes with PDR.Methods:Pooled analysis of PDR eyes from Protocols I, J, N, S, or T wi

Keywords:

Diabetes mellitus
Macular edema
Growth factor
Diabetic retinopathy
Randomized controlled trial
Anti–vascular endothelial growth factor therapy
Retina
Surgery
Medicine
Traction retinal detachment
Ophthalmology
pooled analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations